Two newly announced June dates go some way to alleviating the recent drought in advisory committee meetings outside oncology. Both gatherings of committees under the Office of Neuroscience promise fireworks in a different way.
Key Takeaways
Upcoming FDA Advisory Committee Meetings
-
22 May: The Oncologic Drugs Advisory Committee’s Pediatric Subcommittee will discuss implementation of the 2017 FDARA legislation’s pediatric provisions.
On 4 June, the Psychopharmacologic Drugs Advisory Committee will, for the first time, evaluate an NDA for a psychedelic-assisted therapy...





